InvestorsHub Logo
Followers 0
Posts 9
Boards Moderated 0
Alias Born 08/20/2019

Re: None

Monday, 09/23/2019 3:02:24 PM

Monday, September 23, 2019 3:02:24 PM

Post# of 530
DG33 it appears that you don't have a fundamental understanding of the Hemacare business. It appears The majority of the Hemacare business are derivative blood bank businesses that non-for-profit blood banks in the US can not charge for, because of regulations. Every blood bank has tons of donors and databases. Every blood banks can generate this products in large quantities but can't charge for them. I suspect that for the most part those are available in China without problem. There might be some niche products on a very small scale. So other than the PR value there is nothing there. I would also recommend to you to do some research regarding the money behind Allcells.

I would also recommend you do some research who is on the BOD of Hemacare. I would ask myself why are there two non-for-profit CEOs on the board and what that means for a the possibility on non-possibility of a buyout.

If you look at the history of the blood bank business and Hemacare, you might conclude that Hemacare is on borrowed time until the regulatory environment catches like it did in the past. There is a reason why Hemacare is the only public blood bank related company.

There are more questions. But let's leave some for the future.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.